| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $25.5M | +4.8% | +12.2% |
| SG&A Expense | $7.5M | +4.6% | +26.5% |
| Operating Income | -$32.9M | -4.7% | -15.2% |
| Net Income | -$29.9M | -6.3% | -24.4% |
| EPS (Basic) | -$0.50 | -6.4% | -22.0% |
| EPS (Diluted) | -$0.50 | -6.4% | -22.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $62.0M | -37.1% | -40.4% |
| Current Assets | $281.2M | -6.9% | -23.1% |
| Total Assets | $301.9M | -6.1% | -20.7% |
| Current Liabilities | $15.9M | +15.3% | +28.3% |
| Total Liabilities | $21.3M | +10.3% | +16.6% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$71.5M | — | — |
| Capital Expenditures | $84K | — | — |
| Investing Cash Flow | $38.1M | — | — |
| Financing Cash Flow | $3.4M | — | — |
| Free Cash Flow | -$71.6M | — | — |
| $280.5M |
| -7.2% |
| -22.6% |